Almirall is a global biopharmaceutical company focused on medical dermatology. Founded in 1944 and with headquarters in Barcelona (Spain), our purpose is at the core of our work: “Transform the patients’ world by helping them realize their hopes and dreams for a healthy life”.
Through pharmaceutical innovation, investment in R&D and strong commitment to global healthcare partnerships, we develop and commercialize solutions with specific focus on dermatological diseases such as psoriasis, actinic keratosis, atopic dermatitis or acne. We care and listen to our patients’ needs. We find solutions for them. We aim to empower them.
Almirall has 1 R&D center, 2 chemical plants and 2 pharmaceutical plants. Our more than 1,900 employees make it possible for our treatments to be available in over 100 countries across 5 continents, through our 15 global affiliates and via a strategic partnership network.
Almirall is listed on the Spanish Stock Exchange (ticker: ALM).
Dermatology (Actinic keratosis, Atopic Dermatitis, Eczema, Inflammatory Skin Conditions, Psoriasis, Rosacea, Severe Acne), OTC Products, Other Specialty Areas (e.g. Spasticity in Multiple Sclerosis), and Medical Device
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
Novo Nordisk Pharmaceutical, Pharmaceutical Manufacturing | Novo Nordisk Pharmaceutical, Pharmaceutical Manufacturing | Other 22 Feb 2024 | |